Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
HelixPharma is an Italian biotechnology company and a spin-off from the University of Ferrara that specializes in the research, development, and production of high-quality snail slime (Helix aspersa) extracts for pharmaceutical and dermo-cosmetic applications. The company utilizes a proprietary extraction and purification process to standardize the bioactive components of the secretion, which include allantoin, glycolic acid, collagen, and elastin. Their product portfolio includes medical devices and specialized ingredients targeted at respiratory health, gastrointestinal disorders, and wound healing. HelixPharma's research focuses on the mucoadhesive and regenerative properties of these natural extracts to develop innovative therapeutic solutions. The company is recognized for its cruelty-free extraction methods and its strong academic foundation in chemical and pharmaceutical sciences.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on HelixPharma.